Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 6716547, 11 pages
https://doi.org/10.1155/2018/6716547
Research Article

Angelica gigas Nakai Has Synergetic Effects on Doxorubicin-Induced Apoptosis

1Department of Biological Sciences, Konkuk University, Neungdong-ro 120, Gwangjin-gu, Seoul 05029, Republic of Korea
2Korea Institute of Science and Technology, Gangneung, Gangwondo 25451, Republic of Korea
3Department of Convergence Medicine, Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea
4Korea Hemp Institute, Konkuk University, Konkuk University, Neungdong-ro 120, Gwangjin-gu, Seoul 05029, Republic of Korea
5Department of Advanced Technology Fusion, Konkuk University, Neungdong-ro 120, Gwangjin-gu, Seoul 05029, Republic of Korea

Correspondence should be addressed to Kyungho Lee; rk.ca.kuknok@ohgnuyk and Ye Sun Han; rk.ca.kuknok@nahsy

Received 7 March 2018; Revised 11 July 2018; Accepted 24 July 2018; Published 1 August 2018

Academic Editor: Claudio Tabolacci

Copyright © 2018 Yong-Joon Jeon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Arcamone, G. Cassinelli, G. Fantini et al., “Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. peucetius var. caesius,” Biotechnology and Bioengineering, vol. 11, no. 6, pp. 1101–1110, 1969. View at Publisher · View at Google Scholar · View at Scopus
  2. J. V. McGowan, R. Chung, A. Maulik, I. Piotrowska, J. M. Walker, and D. M. Yellon, “Anthracycline Chemotherapy and Cardiotoxicity,” Cardiovascular Drugs and Therapy, vol. 31, no. 1, pp. 63–75, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Rivankar, “An overview of doxorubicin formulations in cancer therapy,” Journal of Cancer Research and Therapeutics, vol. 10, no. 4, pp. 853–858, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Swain, F. S. Whaley, and M. S. Ewer, “Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials,” Cancer, vol. 97, no. 11, pp. 2869–2879, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Bao, A. Haque, K. Jackson et al., “Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer Model,” The American Journal of Pathology, vol. 178, no. 2, pp. 838–852, 2011. View at Publisher · View at Google Scholar
  6. K. R. Hess et al., “Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer,” Journal of Clinical Oncology, vol. 24, no. 26, pp. 4236–4244, 2007. View at Publisher · View at Google Scholar
  7. W. Hiddemann, M. Kneba, M. Dreyling et al., “Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group,” Blood, vol. 106, no. 12, pp. 3725–3732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. S. Butler, “The role of natural product chemistry in drug discovery,” Journal of Natural Products, vol. 67, no. 12, pp. 2141–2153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kartal, “Intellectual property protection in the natural product drug discovery, traditional herbal medicine and herbal medicinal products,” Phytotherapy Research, vol. 21, no. 2, pp. 113–119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Ganesan, “The impact of natural products upon modern drug discovery,” Current Opinion in Chemical Biology, vol. 12, no. 3, pp. 306–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. W. Li and J. C. Vederas, “Drug discovery and natural products: end of an era or an endless frontier?” Science, vol. 325, no. 5937, pp. 161–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. S. D. Sarker and L. Nahar, “Natural medicine: the genus Angelica,” Current Medicinal Chemistry, vol. 11, no. 11, pp. 1479–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Zhang, L. Li, C. Jiang, C. Xing, S.-H. Kim, and J. Lü, “Anti-cancer and other bioactivities of Korean Angelica gigas Nakai (AGN) and its major pyranocoumarin compounds,” Anti-Cancer Agents in Medicinal Chemistry, vol. 12, no. 10, pp. 1239–1254, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Reddy, S. Kim, M. Hur et al., “Natural Korean Medicine Dang-Gui: Biosynthesis, Effective Extraction and Formulations of Major Active Pyranocoumarins, Their Molecular Action Mechanism in Cancer, and Other Biological Activities,” Molecules, vol. 22, no. 12, p. 2170, 2017. View at Publisher · View at Google Scholar
  15. J. H. Park, Y. J. Lee, and S. J. Keon, “Pharmacognostical studies on the Dang Gui from Korea,” Korean Journal of Pharmacognosy, vol. 36, no. 2, pp. 141–144, 2005. View at Google Scholar · View at Scopus
  16. S.-K. Cho, A. M. A. El-Aty, J.-H. Choi, M. R. Kim, and J. H. Shim, “Optimized conditions for the extraction of secondary volatile metabolites in Angelica roots by accelerated solvent extraction,” Journal of Pharmaceutical and Biomedical Analysis, vol. 44, no. 5, pp. 1154–1158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Yoo, Y. K. Song, H. Jang, D. M. Kim, and S. Y. Byun, “Profiling of skin anti-aging related proteins in human dermal fibroblasts by decursin in Angelica gigas Nakai,” Korean Journal of Chemical Engineering, vol. 28, no. 3, pp. 880–885, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. H. Kim, S.-J. Jeong, H.-Y. Kwon et al., “Decursin prevents cisplatin-induced apoptosis via the enhancement of antioxidant enzymes in human renal epithelial cells,” Biological & Pharmaceutical Bulletin, vol. 33, no. 8, pp. 1279–1284, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Li, W. Li, S. Jung, Y. Lee, and Y. Kim, “Protective Effects of Decursin and Decursinol Angelate against Amyloid β-Protein-Induced Oxidative Stress in the PC12 Cell Line: The Role of Nrf2 and Antioxidant Enzymes,” Bioscience, Biotechnology, and Biochemistry, vol. 75, no. 3, pp. 434–442, 2014. View at Publisher · View at Google Scholar
  20. C. Carvalho, R. X. Santos, S. Cardoso et al., “Doxorubicin: the good, the bad and the ugly effect,” Current Medicinal Chemistry, vol. 16, no. 25, pp. 3267–3285, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Pakos‐Zebrucka, I. Koryga, K. Mnich, M. Ljujic, A. Samali, and A. M. Gorman, “The integrated stress response,” EMBO Reports, vol. 17, no. 10, pp. 1374–1395, 2016. View at Publisher · View at Google Scholar
  22. N. Donnelly et al., “The eIF2alpha kinases: their structures and functions,” Cellular and Molecular Life Sciences, vol. 70, no. 19, pp. 3493–3511, 2013. View at Google Scholar
  23. P. D. Lu, H. P. Harding, and D. Ron, “Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response,” The Journal of Cell Biology, vol. 167, no. 1, pp. 27–33, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Han and R. J. Kaufman, “Physiological/pathological ramifications of transcription factors in the unfolded protein response,” Genes & Development, vol. 31, no. 14, pp. 1417–1438, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Han, S. H. Back, J. Hur et al., “ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death,” Nature Cell Biology, vol. 15, no. 5, pp. 481–490, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. R. S. Y. Wong, “Apoptosis in cancer: from pathogenesis to treatment,” Journal of Experimental & Clinical Cancer Research, vol. 30, no. 1, article 87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. J. Jeon et al., “Salubrinal-Mediated Upregulation of eIF2α Phosphorylation Increases Doxorubicin Sensitivity in MCF-7/ADR Cells,” Molecules and Cells, vol. 39, no. 2, pp. 129–135, 2016. View at Publisher · View at Google Scholar
  29. R. L. Bennett, A. L. Carruthers, T. Hui, K. R. Kerney, X. Liu, and W. S. May, “Increased Expression of the dsRNA-Activated Protein Kinase PKR in Breast Cancer Promotes Sensitivity to Doxorubicin,” PLoS ONE, vol. 7, no. 9, Article ID e46040, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. A. C. Palmer and P. K. Sorger, “Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy,” Cell, vol. 171, no. 7, pp. 1678–1682.e13, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Elmore, “Apoptosis: a review of programmed cell death,” Toxicologic Pathology, vol. 35, no. 4, pp. 495–516, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Sowndhararajan, P. Deepa, M. Kim, S. J. Park, and S. Kim, “A Review of the Composition of the Essential Oils and Biological Activities of Angelica Species,” Scientia Pharmaceutica, vol. 85, no. 3, p. 33, 2017. View at Publisher · View at Google Scholar
  33. J. Couturier, M. Morel, R. Pontcharraud et al., “Interaction of Double-stranded RNA-dependent Protein Kinase (PKR) with the Death Receptor Signaling Pathway in Amyloid β (Aβ)-treated Cells and in APP,” The Journal of Biological Chemistry, vol. 285, no. 2, pp. 1272–1282, 2010. View at Publisher · View at Google Scholar
  34. J. Couturier, M. Paccalin, M. Morel et al., “Prevention of the β-amyloid peptide-induced inflammatory process by inhibition of double-stranded RNA-dependent protein kinase in primary murine mixed co-cultures,” Journal of Neuroinflammation, vol. 8, no. 1, p. 72, 2011. View at Publisher · View at Google Scholar
  35. C.-H. Yoon, E.-S. Lee, D.-S. Lim, and Y.-S. Bae, “PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 106, no. 19, pp. 7852–7857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. J. Kim, K. M. Park, N. Kim, and Y. I. Yeom, “Doxorubicin prevents endoplasmic reticulum stress-induced apoptosis,” Biochemical and Biophysical Research Communications, vol. 339, no. 2, pp. 463–468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Hetz, “The unfolded protein response: controlling cell fate decisions under ER stress and beyond,” Nature Reviews Molecular Cell Biology, vol. 13, no. 2, pp. 89–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Qing, B. Li, A. Vu et al., “ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation,” Cancer Cell, vol. 22, no. 5, pp. 631–644, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. J. L. Armstrong, R. Flockhart, G. J. Veal, P. E. Lovat, and C. P. F. Redfern, “Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells,” The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6091–6100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Li, Y. Guo, J. Tang, J. Jiang, and Z. Chen, “New insights into the roles of CHOP-induced apoptosis in ER stress,” Acta Biochimica et Biophysica Sinica, vol. 46, no. 8, pp. 629–640, 2014. View at Publisher · View at Google Scholar
  41. Z. Xu, Y. Bu, N. Chitnis, C. Koumenis, S. Y. Fuchs, and J. A. Diehl, “miR-216b regulation of c-Jun mediates GADD153/CHOP-dependent apoptosis,” Nature Communications, vol. 7, p. 11422, 2016. View at Publisher · View at Google Scholar
  42. A. R. Safa and K. E. Pollok, “Targeting the anti-apoptotic protein c-FLIP for cancer therapy,” Cancers, vol. 3, no. 2, pp. 1639–1671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. N.-H. Yim, J. H. Lee, W.-K. Cho, M. C. Yang, D. H. Kwak, and J. Y. Ma, “Decursin and decursinol angelate from Angelica gigas Nakai induce apoptosis via induction of TRAIL expression on cervical cancer cells,” European Journal of Integrative Medicine, vol. 3, no. 4, pp. e293–e301, 2011. View at Google Scholar · View at Scopus
  44. K. D. McCullough, J. L. Martindale, L. O. Klotz, T. Y. Aw, and N. J. Holbrook, “Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bc12 and perturbing the cellular redox state,” Molecular and Cellular Biology, vol. 21, no. 4, pp. 1249–1259, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Gotoh, K. Terada, S. Oyadomari, and M. Mori, “hsp70-DnaJ chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria,” Cell Death & Differentiation, vol. 11, no. 4, pp. 390–402, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Jiang, J. Piao, H.-J. Cho, W.-S. Kang, and H.-Y. Kim, “Improvement in antiproliferative activity of Angelica gigas Nakai by solid dispersion formation via hot-melt extrusion and induction of cell cycle arrest and apoptosis in HeLa cells,” Bioscience, Biotechnology, and Biochemistry, vol. 79, no. 10, pp. 1635–1643, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Jang, S.-J. Jeong, H.-Y. Kwon et al., “Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 506324, 13 pages, 2013. View at Publisher · View at Google Scholar
  48. H. S. Choi, S.-G. Cho, M. K. Kim et al., “Decursin in Angelica gigas Nakai (AGN) Enhances Doxorubicin Chemosensitivity in NCI/ADR-RES Ovarian Cancer Cells via Inhibition of P-glycoprotein Expression,” Phytotherapy Research, vol. 30, no. 12, pp. 2020–2026, 2016. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Kim, M. Yun, E.-O. Kim et al., “Decursin enhances TRAIL-induced apoptosis through oxidative stress mediated- endoplasmic reticulum stress signalling in non-small cell lung cancers,” British Journal of Pharmacology, vol. 173, no. 6, pp. 1033–1044, 2016. View at Publisher · View at Google Scholar · View at Scopus
  50. S. H. Son, M.-J. Kim, W.-Y. Chung et al., “Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase,” Cancer Letters, vol. 280, no. 1, pp. 86–92, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. S. H. Son, K.-K. Park, S. K. Park et al., “Decursin and decursinol from Angelica gigas inhibit the lung metastasis of murine colon carcinoma,” Phytotherapy Research, vol. 25, no. 7, pp. 959–964, 2011. View at Publisher · View at Google Scholar · View at Scopus